Refractory Follicular Lymphoma Diagnostics Market Size, Share, and Industry Analysis, By Product (Instruments and Kits & Consumables), By Method (Immunohistochemistry (ICH), In situ Hybridization (ISH), Polymerase Chain Reaction (PCR), and Others), By End-user (Hospitals, Diagnostic Centers, and Others), and Regional Forecast, 2025-2032

Follicular lymphoma (FL) is a slow-growing type of non-Hodgkin lymphoma that typically presents with asymptomatic peripheral lymphadenopathy. It is the second most common type of non-Hodgkin lymphoma, accounting for 10-20% of the cases across the globe. It develops when the white blood cells cluster together to form lumps in the lymph glands or organs. There are two types of follicular lymphoma: relapsed and refractory. The term relapsed is the disease that reappears after a period of remission, and refractory is when the lymphoma does not respond to early treatment or the response to treatment does not last very long. The diagnoses for both types are similar, such as imaging and in-vitro diagnostic techniques using lymph node biopsies.

The follicular lymphoma diagnostic market is expected to experience steady growth in the coming years as the demand for accurate and early diagnosis of this type of cancer increases. Factors driving the growth of the follicular lymphoma diagnostics market include an increasing prevalence of the disease, advancements in diagnostic technologies, and a growing awareness of the importance of early detection for improved patient outcomes. Additionally, collaborations between healthcare organizations and research institutions to develop innovative diagnostic tools and treatments for follicular lymphoma are expected to fuel market growth further.

• For instance, in June 2020, F. Hoffmann-La Roche Ltd. received the U.S. FDA approval for their cobas EZH2 Mutation Test to be utilized as a companion diagnostic for patients suffering from follicular lymphoma. This test is to be used as a companion diagnostic for the therapeutic of TAZVERIK (tazemetostat), which is developed by Epizyme, Inc. TAZVERIK (tazemetostat) is indicated for the “adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies”. It is also approved for adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatments.

The COVID-19 pandemic significantly disrupted healthcare services globally and negatively impacted refractory follicular lymphoma diagnostics across the globe. This disruption led to unprecedented challenges in terms of maintaining essential cancer care services, including diagnostics. However, the resumption of diagnostic services boosted the market growth in 2021, and the ongoing advancements are expected to grow the market continuously over the forecast period.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Refractory Follicular Lymphoma, By Key Countries/Region, 2023
• Key Industry Developments- Mergers, Acquisitions, and Partnerships
• Overview: Advancements in the Follicular Lymphoma Diagnosis
• Impact of COVID-19 on the Market

Analysis by Product

Based on product, the market is classified into instruments and kits & consumables. The kits & consumables segment held a significant market share in 2023. The segments include antibodies, probes, and assays, reagents & kits. The segmental growth can be attributed to the high prevalence of refractory follicular lymphoma and the increasing demand for accurate & technologically superior diagnostic products. Moreover, the increasing R&D investments in cancer diagnostics are leading to the development of advanced kits and reagents, which is expected to result in market growth.

The instruments segment is projected to witness considerable growth in the coming years due to technological advancements and device launches with higher accuracies. The development of innovative instruments that incorporate cutting-edge technologies coupled with their increasing availability and affordability for healthcare providers and patients is anticipated to drive the market. This increased accessibility is anticipated to propel the growth of the market.

• For instance, in August 2022, Roche Diagnostics launched the Digital LightCycler System, a digital polymerase chain reaction (PCR) system to detect rare mutations, supporting early cancer diagnosis of several forms of cancers.

Regional Analysis

To gain extensive insights into the market, Download for Customization

The global market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for a significant share in 2023. The region’s growth is attributed to the high diagnostic rate of these cancers in the region and the rapid development of innovative cancer diagnostic solutions in the U.S. Moreover, the market growth is expected to be driven by the presence of major industry players and advanced product launches in the region.

• For instance, according to the article published in Blood in November 2023, the estimated prevalence of follicular lymphoma in 2022 was 154,922. Such a high prevalence of follicular lymphomas is expected to drive the market in the coming years.

The Asia Pacific market is expected to grow at the highest CAGR over the projected years. Some of the contributive reasons include the rising prevalence of refractory follicular lymphomas and the increasing rate of cancer diagnoses in the region. Furthermore, the growing awareness of early cancer detection in the region is expected to drive market growth. Moreover, the rising number of diagnostic centers and the growing adoption of advanced instruments in the region is expected to drive the market significantly in the coming years.

Key Players Covered

• The report includes key players, such as Beckman Coulter, Inc. (Danaher Corporation), Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Illumina Inc., F. Hoffmann-La Roche, QIAGEN, and Abcam Limited.

Key Industry Developments

• In November 2023, Illumina Inc. launched an advanced liquid biopsy assay, the new TruSight Oncology 500 ctDNA v2, for complete genomic profiling of solid tumors.
• In October 2023, QIAGEN partnered with Myriad Genetics, Inc. to develop companion diagnostic tests in the field of cancers.
• In June 2022, F. Hoffmann-La Roche launched the new BenchMark ULTRA PLUS system, an advanced tissue staining platform for cancer diagnostics.